Neurocrine Biosciences, Inc. reported significant financial growth in its 2025 fiscal year, with total revenues reaching $2.86 billion, a 21.6% increase from $2.36 billion in 2024. This growth was primarily driven by strong sales of its flagship product, INGREZZA, which generated $2.51 billion in net product sales, up from $2.31 billion in the previous year. The company also saw the successful launch of CRENESSITY, which contributed $301.2 million in its first full year of sales. The increase in revenues was partially offset by a lower net price due to new market access investments aimed at supporting long-term growth.
In terms of profitability, Neurocrine reported an operating income of $619.1 million for 2025, compared to $570.5 million in 2024. The net income for the year was $478.6 million, translating to diluted earnings per share of $4.67, up from $3.29 in the prior year. The company’s operating expenses also increased, totaling $2.24 billion, reflecting continued investments in research and development, as well as the expansion of its commercial organization.
Strategically, Neurocrine has made several key developments, including the planned expansion of its sales teams for INGREZZA and CRENESSITY, expected to be completed by the end of the first quarter of 2026. The company appointed Dr. Sanjay Keswani as Chief Medical Officer in June 2025, further strengthening its executive team. Additionally, Neurocrine has been proactive in managing its capital, authorizing a $500 million share repurchase program in February 2025, following a $300 million accelerated share repurchase program completed earlier that year.
Operationally, Neurocrine has expanded its workforce significantly, growing from approximately 200 employees in 2017 to around 2,000 by the end of 2025. The company’s commercial strategy focuses on maximizing the potential of INGREZZA and CRENESSITY, with an emphasis on effective execution and understanding the underlying biology of the diseases they target. The company also reported that it has improved formulary access for INGREZZA, enhancing coverage for approximately 70% of Medicare beneficiaries affected by tardive dyskinesia and Huntington's disease.
Looking ahead, Neurocrine remains optimistic about its growth trajectory, supported by a robust pipeline of product candidates in various stages of development. The company aims to continue delivering innovative treatments for neurological, psychiatric, endocrine, and immunological disorders, with plans to launch new therapies approximately every two years. However, the company acknowledges potential risks, including regulatory challenges and market competition, which could impact its future performance.
About NEUROCRINE BIOSCIENCES INC
Neurocrine Biosciences is a biopharmaceutical company specializing in neuroscience. It develops and commercializes treatments for neuropsychiatric, neurological, and neuroendocrine disorders, including FDA-approved drugs like INGREZZA for tardive dyskinesia and Huntington's chorea, and CRENESSITY for congenital adrenal hyperplasia. The company focuses on innovative pipelines across small molecules, peptides, proteins, antibodies, and gene therapies, serving global markets with a competitive edge in rare and underserved neurological conditions.
About 10-K Filings
A 10-K form is a comprehensive annual report that public companies in the United States must file with the SEC, providing a detailed overview of the company's financial condition, performance, and business strategies.
Key points about the 10-K:
- Frequency: Filed annually, typically within 60 to 90 days after the end of the company's fiscal year.
-
Content: It includes:
- Detailed financial statements audited by an independent accounting firm
- Management's Discussion and Analysis (MD&A) of financial condition and results
- Description of the company's business, properties, and legal proceedings
- Risk factors and market risks
- Executive compensation and corporate governance information
- Importance: Considered the most comprehensive and important document a public company files with the SEC.
- Length: Often exceeds 100 pages due to its extensive and detailed nature.
Our Methodology
AssetRoom is committed to providing timely summaries of news from public companies. We use AI to generate these summaries quickly, but they are not reviewed by human experts.
Our method:
- Data Collection: We continuously monitor for new filings (currently limited to US-listed stocks).
- AI-Powered Analysis: Our advanced AI system processes each filing, identifying key information and extracting relevant data.
- Summary Generation: The AI creates a concise, easy-to-understand summary of the filing, highlighting the most important points.
- Publication: The summary is immediately published on our platform, allowing users instant access to the latest information.
- Email users: We distribute round-up emails according to our users preferences, keeping them in the loop with the companies they follow.
Feedback & Corrections
Spot an error or have a suggestion? Contact us.